RecruitingNot ApplicableNCT04798651
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
Sponsor
University Hospital, Bordeaux
Enrollment
150 participants
Start Date
Sep 30, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- male or female subjects ;
- Age ≥ 18 years;
- subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome;
- patients for which a blood draw and / or lumbar puncture to collect CSF is performed for diagnostic or therapeutic purpose;
- affiliated to an health insurance system;
- and who agree to participate in the study.
Exclusion Criteria2
- Pregnant or breastfeeding women,
- patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
Interventions
BIOLOGICALblood sample
28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
BIOLOGICALcerebro-spinal fluid
1 ml of cerebro-spinal fluid
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04798651
Related Trials
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT048734921 location
Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment
NCT067824641 location
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT074776392 locations
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
NCT072071481 location